Navigation Links
ChemoCentryx Announces 2011 Fourth Quarter and Full Year Financial Results
Date:3/30/2012

not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's Annual Report on Form 10-K, which we intend to file with the Securities and Exchange Commission tomorrow and which will be available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.ChemoCentryx.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CCXI – GContacts:Susan M. Kanaya

Burns McClellanSenior Vice President, Finance and

Media InquiriesChief Financial Officer or

Kathy Nugent, Ph.D.Markus J. Cappel, Ph.D.

212-213-0006Chief Business Officer

knugent@burnsmc.com 650-210-2900investor@chemocentryx.comChemoCentryx, Inc. Consolidated Statement of Operations Data (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2011 2010 2011 2010 Consolidated Statement of Operations Data: Revenues: Collaborative research and development revenue from related party  

$
26,052$
3,115$
31,673$
34,861 Total revenues:

26,05213,11531,67334,861 Operating expenses: Research and development  

5,4458,14228,35933,527 General and administrative  

1,8941,9297,6157,292 Total operating expenses  

7,33910,07135,97440,819 Income (loss) from operations  

18,7133,
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 /PRNewswire-USNewswire/ ... that allows Kessler Foundation and New Jersey Health ... research, education and patient care programs has been ... chief executive officer of Kessler Foundation and ... Health Foundation. "The experience of New ...
(Date:9/30/2014)... 2014  Georgia-Pacific Professional is a leading provider ... a wide range of away from home applications. ... in healthcare, including hospitals, long-term care facilities, surgical ... its healthcare products and solutions to the dental ... of infection control in the dental office," said ...
(Date:9/30/2014)... -- In a recent study it was ... the Eldor spinal needle 25G, 103 mm appeared significantly ... spinal needles of the same gauge and length of ... an excellent type of regional anesthesia for many operations ... It is estimated that 100 million patients worldwide ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... SPRING, Md., June 24, 2011 Breast cancer patients and ... 7:00 am outside of the Federal Drug Administration (FDA).  At ... anti-cancer drug Avastin from the approved medication list for treatment ... in 2008 for use to treat breast cancer. ...
...   - Dossier Re-Examination ... a leader in,the field of human gene therapy, ... its Marketing Authorisation Application,(MAA) for Glybera® (alipogene tiparvovec) ... Following a recent,meeting with the European Medicines Agency,s ...
Cached Medicine Technology:Breast Cancer Patients and Families Stand Up To FDA 2Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application 2Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application 3Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application 4
(Date:9/30/2014)... 30, 2014 ADOAMNI, Inc. ... campaign through GoFundMe. The campaign, which surpassed its goal ... portion of the funds necessary to convert a diesel ... Stockton Unified School District (SUSD). The campaign rallied citizens ... portion of the funds necessary for the conversion of ...
(Date:9/30/2014)... 2014 The American Parkinson ... funding supporting seven Research grants to junior investigators ... to support post-doctoral scientists whose research training holds ... etiology and treatment of Parkinson’s disease, and eight ... and medical centers across the country intended to ...
(Date:9/30/2014)... With accolades like the Most Inspirational Lash Artist ... Brand of My Brand Lashes is a leader of lash ... the ability to teach. She leads with a passion for ... reputation. , With a background in Cosmetology that spans 11 ... and as an Instructor. She has operated two of her ...
(Date:9/30/2014)... Got grapes? UCLA researchers have demonstrated how resveratrol, an ... to inhibit growth of the bacteria that causes acne. ... a common acne medication, benzoyl peroxide, may enhance the ... into new treatments. , Published in the current online ... the early lab findings demonstrated that resveratrol and benzoyl ...
(Date:9/30/2014)... -- MIT engineers have devised a way to rapidly ... making it easier to discover promising new ways to ... antibodies, peptides, RNA, and DNA, to human patients. , ... Biology , the researchers used this technology to identify ... also to rodents. This type of high-speed screen could ...
Breaking Medicine News(10 mins):Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 2Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 4Health News:My Brand Lashes and Lash Affair By J. Paris Merge to Offer Premium Lash and Brow Products and Certifications 2Health News:My Brand Lashes and Lash Affair By J. Paris Merge to Offer Premium Lash and Brow Products and Certifications 3Health News:Antioxidant found in grapes uncorks new targets for acne treatment 2Health News:Antioxidant found in grapes uncorks new targets for acne treatment 3Health News:High-speed drug screen 2Health News:High-speed drug screen 3
... (NP) is pleased to share today the release of Mr. Umar ... the Mindanao region of the Philippines who was kidnapped from the ... 13. Jaleel is alive and is currently en route to ... the vicinity of Tipo Tipo on Basilan. Jaleel was released ...
... , ... final program for Biopolymers Symposium 2009 taking place September 28 - 30th in Chicago, ... ... -- IntertechPira is pleased to announce the Biopolymers Symposium 2009 conference and exhibit, taking ...
... A. Magana awarded $25,000 each for leadership in increasing diversity ... 3 Guillermo J. Camacho, a dentist in West Covina, ... at California State Polytechnic University, Pomona, that encourages students of ... founded and directs a program at Cabrillo College ...
... if you,re a woman trying to figure out how to please her ... the gift you really want for yourself. , , (Photo: ... that probably rules out the ,65 Mustang and the even-bigger screen TV. ... for millions of women - one that would actually be a true ...
... for early confirmation of bile duct, pancreatic cancers, , WEDNESDAY, ... have developed new tests that make it easier to diagnose ... study, the new tests more than doubled the detection rate ... are not discovered until their later stages. , "The earlier ...
... , Health insurer chooses Cincom Eloquence to streamline policy ... software provider Cincom Systems announces that Medica ( ... to more than 1.5 million members, has chosen Cincom ... document automation processes. , , Key considerations for ...
Cached Medicine News:Health News:Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 2Health News:Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 3Health News:Biopolymers Symposium 2009 Announces Final Program and Interactive Green Brochure 2Health News:Mentors Who Support Students Receive TCWF Champions of Health Professions Diversity Award 2Health News:Mentors Who Support Students Receive TCWF Champions of Health Professions Diversity Award 3Health News:Perfect Father's Day Gift: The Sound of Silence 2Health News:Perfect Father's Day Gift: The Sound of Silence 3Health News:New Tests Spot Tough-to-Detect Cancers Sooner 2Health News:Medica Selects Cincom's Document Automation Software 2Health News:Medica Selects Cincom's Document Automation Software 3
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
Pipetman 8X200 Multichannel Pipette is an eight-channel, fully adjustable, air-displacement pipette having a useful volume range from 20 L to 200 L. Robustwith the usual Gilson qualities this pipette...
... multichannel pipettes speed up ... into microplates, with super ... volumes. The improved ergonomic ... multichannels, combined with super ...
Medicine Products: